News 
Market Data 
Discover
Replies to post #225976 on Biotech Values
Identifying extrahepatic targeting ligands to target other tissues outside of the liver is the next big challenge RNAi companies are facing. Arrowhead has been working hard in being able to advance its RNAi TRiM™ platform to the next level by going extrahepatic. The Company is currently guiding on the delivery of two new extrahepatic drugs in the clinic, ARO-HIF2 (2019) for the treatment of clear cell renal cell carcinoma (ccRCC), and ARO-ENaC (1H2020) for the treatment of cystic fibrosis.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has been able to identify high-affinity targeting ligands that can target cancerous tumors, as well as the lungs. On August 15, 2019 the U.S. Patent and Trademark Office published Arrowhead’s latest patent application, Publication No. 20190248832 for Alpha-V Beta-6 Integrin Ligands and Uses Thereof.
If the developed compositions of the avß6 integrin ligands turn out to be as successful as Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is beginning to show in its preliminary data for ARO-ENaC, this patent application can potentially have profound implications for extrahepatic targeting of RNAi. An issued patent would provide Arrowhead with a legal monopoly and allow it to corner the market with its newly developed extrahepatic targeting compositions for around 17 years.
If Arrowhead can establish a monopoly with its newly developed extrahepatic compositions, this new patent application has the potential to be a blockbuster.
11/08/19 10:44 AM
(note the second bullet point in partcular)$ARWR HBV data out at #AASLD19 #LiverMtg19
— Andy Biotech (@AndyBiotech) November 8, 2019
1) Are they really calling this "dose response" from 100mg to 400mg with a straight face?https://t.co/kqB9nPETqP
2) Is JNJ-6379 CAM triple combo adding anything there?
-1.7log reduction looks same as duo combohttps://t.co/rxsF9kAsFX pic.twitter.com/1iKMZmv164
